AC Immune reported positive interim data from the Phase 2 VacSYn trial of ACI-7104.056 for early Parkinson's disease treatment. Encouraging safety and immunogenicity results were observed, indicating potential benefits for patients. Future updates are expected in H1 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing